| serogroup b meningococcal disease--oregon, 1994. | in oregon, the incidence of meningococcal disease has increased substantially, more than doubling from 2.2 cases per 100,000 persons in 1992 to 4.6 per 100,000 in 1994--the highest incidence in oregon since 1943. this incidence was almost fivefold higher than recent estimates for the united states during 1989-1991 (approximately one case per 100,000 persons annually) (1). this report describes meningococcal disease surveillance data from 1994 and summarizes epidemiologic and laboratory data on s ... | 1995 | 7845348 |
| group a meningococcal disease in the u.s. pacific northwest: epidemiology, clinical features, and effect of a vaccination control program. | in 1975 an outbreak of group a meningococcal disease began in seattle, washington, and cases subsequently were recognized throughout the pacific northwest. nearly one-half of the affected persons were native americans; two-thirds were alcohol abusers and/or habitués of skid road communities. in seattle, group a meningococci colonized asymptomatic persons only if these individuals had contact with skid road (p = .006). the epidemic strain may have spread from american indians in manitoba, canada. ... | 1984 | 6209769 |
| leads from the mmwr. plasmid-mediated tetracycline-resistant neisseria gonorrhoeae--georgia, massachusetts, oregon. | | 1986 | 3086581 |
| plasmid-mediated tetracycline-resistant neisseria gonorrhoeae--georgia, massachusetts, oregon. | | 1986 | 3084943 |
| epidemic-associated neisseria meningitidis detected by multilocus enzyme electrophoresis. | | 1995 | 8903159 |
| epidemic serogroup b meningococcal disease in oregon: the evolving epidemiology of the et-5 strain. | in 1993, oregon's incidence of serogroup b meningococcal disease began to rise because of a highly clonal group of strains designated enzyme type 5 (et-5), the first such increase observed in the united states. | 1999 | 10227318 |
| distribution of neisseria meningitidis serogroup b serosubtypes and serotypes circulating in the united states. the active bacterial core surveillance team. | because the neisseria meningitidis serogroup b (nmsb) capsule is poorly immunogenic in humans, immunization strategies have focused on noncapsular antigens. both pora and to a lesser extent porb are noncapsular protein antigens capable of inducing protective bactericidal antibodies, and vaccines based on the outer membrane protein (omp) components of serogroup b meningococci have been shown to be effective in clinical trials. multiple pora antigens seem to be needed to prevent endemic meningococ ... | 2000 | 10970378 |
| activity of faropenem tested against neisseria gonorrhoeae isolates including fluoroquinolone-resistant strains. | we evaluated the anti-gonococcal potency of faropenem along with 7 comparator reference antimicrobials against a preselected collection of clinical isolates. the 265 isolates were inclusive of 2 subsets: 1) 76 well-characterized resistant phenotypes of gonococcal strains (53 quinolone-resistant strains--31 with documented quinolone resistance-determining region changes from japan, 15 strains resistant to penicillin and tetracycline, and 8 strains with intermediate susceptibility to penicillin) a ... | 2005 | 16269221 |
| risk factors for meningococcal disease in students in grades 9-12. | meningococcal disease is a serious problem in adolescents, including high school students. universal immunization of adolescents with meningococcal conjugate vaccine was recently recommended. we studied risk factors for meningococcal disease in students in grades 9-12. | 2008 | 18277925 |